Merus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth Potential

Merus N.V. (NASDAQ:MRUS) ranks among the best biotech stocks to buy. On September 17, Barclays began coverage of Merus N.V. (NASDAQ:MRUS) with a price target of $112 and an Overweight rating. Barclays pointed out that the approval of zenocutuzumab for rare malignancies has commercially validated Merus’s platform.

According to Barclays, Merus’s Phase 3 clinical asset, petosemtamab, is being investigated through two potentially registration-enabling Phase 3 trials for frontline and previously treated metastatic head and neck cancers.

With petosemtamab undergoing clinical derisking in head and neck malignancies and possible value creation in colorectal cancer through year-end 2026, the firm sees a substantial opportunity for share gain.

Merus NV (NASDAQ:MRUS) is a biotechnology company that develops antibody-based cancer treatments. It has several initiatives in the works, including Zenocutuzumab and Petosemtamab (MCLA-158).

While we acknowledge the potential of MRUS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.